Septerna, Inc. (SEPN)

NGM – Цена в реальном времени. Валюта: USD

24.84

+1.27 (5.39%)

При закрытии: May 12, 2026, 4:00 PM EDT

25.50

+0.66 (2.66%)

До открытия: May 13, 2026, 5:33 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Septerna, Inc. (SEPN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Septerna, Inc. (SEPN)

Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

Septerna to Present at Bank of America Securities Health Care Conference

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Видео

No Data

Пресс-релизы

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

Search stocks

Septerna, Inc. (SEPN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Septerna, Inc. (SEPN)

Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

Septerna to Present at Bank of America Securities Health Care Conference

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Видео

No Data

Пресс-релизы

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy